Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. VEGF-C as a putative therapeutic target in cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Application of cell-free DNA for genomic tumor profiling: a feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Algorithmic Clustering Of Single-Cell Cytometry Data-How Unsupervised Are These Analyses Really?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Getting the Most from Your High-Dimensional Cytometry Data

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The anatomy of single cell mass cytometry data

    Research output: Contribution to journalReviewpeer-review

  5. Analysis of Mass Cytometry Data

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Anders Handrup Kverneland
  • Magnus Pedersen
  • Marie Christine Wulff Westergaard
  • Morten Nielsen
  • Troels Holz Borch
  • Lars Rønn Olsen
  • Gitte Aasbjerg
  • Saskia J Santegoets
  • Sjoerd H van der Burg
  • Katy Milne
  • Brad H Nelson
  • Özcan Met
  • Marco Donia
  • Inge Marie Svane
View graph of relations

Immune therapy is a promising field within oncology but has been unsuccessful in ovarian cancer (OC). Still, there is rationale and evidence supporting immune therapy in OC. We investigated the potential for adoptive cell therapy (ACT) from in vitro expanded tumor-infiltrating lymphocytes (TILs) in combination with checkpoint inhibitors (ICI) and conducted immunological testing of ex vivo expanded TILs (REP-TILs). Six patients with late-stage metastatic high-grade serous OC were treated with immune therapy consisting of ipilimumab followed by surgery to obtain TILs and infusion of REP-TILs, low-dose IL-2 and nivolumab. One patient achieved a partial response and 5 others experienced disease stabilization for up to 12 months. Analysis of the REP-TILs with flow- and mass-cytometry show primarily activated and differentiated effector memory T cells. REP-TILs showed in vitro reactivity and expression of inhibitory receptors, such as LAG-3 and PD-1. Furthermore, our data indicate that addition of ipilimumab therapy improves the T cell fold expansion during production, increase the level of CD8 T cell tumor reactivity, and favorably affect the T cell phenotype. We show that the combination of ICI and ACT is feasible and safe. With one partial response and one long-lasting SD, we demonstrated the potential of ACT in OC.

Original languageEnglish
JournalOncotarget
Volume11
Issue number22
Pages (from-to)2092-2105
Number of pages14
ISSN1949-2553
DOIs
Publication statusPublished - 2 Jun 2020

ID: 61244004